<DOC>
	<DOCNO>NCT01722331</DOCNO>
	<brief_summary>This study conduct evaluate efficacy safety/tolerability subcutaneous MK-3222 , follow optional long-term safety extension study , participant moderate-to-severe chronic plaque psoriasis .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Subcutaneous MK-3222 , Followed Optional Long-Term Safety Extension Study , Participants With Moderate-to-Severe Chronic Plaque Psoriasis ( MK-3222-010 )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Clinical diagnosis moderatetosevere plaque psoriasis least 6 month prior study enrollment A candidate phototherapy systemic therapy For extension study : must complete Part 3 base study For extension study : must achieve least PASI50 response end Part 3 base study For extension study : must receive active MK3222 treatment within 12 week prior end Part 3 base study Premenopausal female participant must agree abstain heterosexual activity use medically accept method contraception use appropriate effective contraception per local regulation guideline If enrol Japanese site , participant psoriatic arthritis use nonsteroidal antiinflammatory drug ( NSAIDs ) must stable dose least 4 week prior first dose study drug must expect require increase dose course study Has erythrodermic psoriasis , predominantly pustular psoriasis , medicationinduced medicationexacerbated psoriasis , new onset guttate psoriasis Current history severe psoriatic arthritis wellcontrolled current treatment Women childbearing potential pregnant , intend become pregnant within 6 month complete trial , breast feeding Expected require topical treatment , phototherapy , systemic treatment trial Presence infection History recurrent infection require treatment systemic antibiotic within 2 week screen Previous use MK3222 IL23/Th17 pathway inhibitor include P40 , p19 , IL17 antagonists Evidence active untreated latent tuberculosis ( TB ) Positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBs Ag ) hepatitis C virus ( HCV ) At Japanese site , positive test HBs antibody hepatitis B virus ( HBV ) deoxyribonucleic acid ( DNA ) At Japanese site , positive test Hepatitis B core ( HBc ) antibody HBV DNA For extension study : woman childbearing potential pregnant , intend become pregnant within 6 month complete trial , breast feeding For extension study : active uncontrolled significant organ dysfunction clinically significant laboratory abnormality For extension study : expect require topical treatment , phototherapy , systemic treatment extension study At Japanese site , abnormal Beta D Glucan and/or KL6 test result ( ) screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>